Treasury Board of Canada Secretariat
www.tbs-sct.gc.ca
Common menu bar links
Breadcrumb Trail
ARCHIVED - Patented Medicine Prices Review Board - Supplementary Tables
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Sources of Non-Respendable Revenue
| Program Activity | ($ thousands) | |||
|---|---|---|---|---|
| Forecast Revenue 2011-12 |
Planned Revenue 2012-13 |
Planned Revenue 2013-14 |
Planned Revenue 2014-15 |
|
| Patented Medicines Price Regulation Program | ||||
| Voluntary Compliance Undertakings | $10,907.01 | - | - | - |
| Refunds of amounts credited to revenues in previous years | (2,512.9)2 | |||
| Total Non-respendable Revenue | $8,394.1 | - | - | - |
-
1 The money reported as non-respendable revenue does not represent revenues generated by the PMPRB. This money is a result of payments made by patentees to the Government of Canada through Voluntary Compliance Undertakings (VCUs) or Board orders to offset excess revenues. The Minister of Health may enter into agreements with any province or territory respecting the distribution to that province/territory of amounts received by the Receiver General, less any costs incurred in relation to the collection and distribution of those amounts.
-
2 Following a hearing of the Board conducted in 2008-2009 pursuant to the Patent Act, the Board concluded that the patentee had sold two patented medicines in Canada at excessive prices. The patentee was ordered by the Board to pay the amount of $2,512.9 thousand to the Crown. The patentee complied with the Board Order but applied for judicial review of the Order. The Federal Court quashed the Board Order and directed in its judgment that the sum of $2,512.9 thousand be returned promptly to the patentee with appropriate interest and specified costs.
